Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5‐fluorouracil and oral capecitabine

Ramani, V. S.; Myint, Arthur Sun; Montazeri, A; Wong, Helen

doi:10.1111/j.1463-1318.2010.02323.x

Cited by 16 publications

(19 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there were heterogeneities between these trials ( I = 53%, P = 0.05). Four trials [12, 15, 18, 19] reported N downstaging (the reduction of the N stage by at least one level after neoadjuvant chemoradiation); random-effect pooled estimate demonstrated an increased OR for capecitabine as well (OR, 2.06; 95% CI, 1.34–3.16; P = 0.001) (Figure 5). …”

Section: Resultsmentioning

confidence: 99%

“…Four trials [12, 14, 16, 19] provided data for disease-free survival; however, Kaplan-Meier plots of disease-free survival were only available in 3 trials [12, 14, 19], including 690 patients (capecitabine, n = 330; 5-FU, n = 360). The meta-analysis of the pooled data demonstrated that the 3-year disease-free survival was in favour of capecitabine-based regimens (HR, 0.65; 95% CI, 0.44–0.96, P = 0.03; Figure 7).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis

Liu

Yan

et al. 2016

Gastroenterology Research and Practice

View full text Add to dashboard Cite

A meta-analysis was carried out to compare the efficacy and safety of capecitabine plus radiation with 5-fluorouracil (5-FU) plus radiotherapy (RT) as neoadjuvant treatment in locally advanced rectal cancer (LARC). We searched the Cochrane database, Ovid, Medline, Embase, ISI databases, and Chinese Biomedical Literature Database between January 1998 and October 2014. Trials of capecitabine compared with 5-FU plus RT as neoadjuvant treatment for LARC were considered for inclusion. RevMan software was used to analyze these data. Nine trials were included in this meta-analysis, which covered a total of 3141 patients. The meta-analysis showed that capecitabine group had statistically significant better pCR rates (OR, 1.34; 95% CI, 1.10–1.64; P = 0.003), T downstaging rates (OR, 1.58; 95% CI, 1.22–2.06; P = 0.0007), N downstaging rates (OR, 2.06; 95% CI, 1.34–3.16; P = 0.001), less distant metastasis (OR, 0.63; 95% CI, 0.44–0.88; P = 0.007), and lowered leucocytes (OR, 0.25; 95% CI, 0.11–0.54; P = 0.0005), but with higher incidence of hand-foot syndrome (HFS) (OR, 4.43; 95% CI, 1.59–12.33; P = 0.004). Capecitabine was more efficient than 5-FU in terms of tumor response in neoadjuvant treatment for patients with LARC and favourably low toxicity with the exception of HFS.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis

Liu

Yan

et al. 2016

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…Infusional 5-FU has been compared to Capecitabine in various trials. 13,14 The addition of oxaliplatin in neoadjuvant chemoradiation of rectal cancer has only added to the toxicity without any added benefit. 15 The published literature with respect to preoperative chemoradiation of rectal cancer is very scanty from India.…”

Section: Discussionmentioning

confidence: 99%

Comparison of continuous infusional 5-fluorouracil and capecitabine in preoperative chemo radiotherapy for locally advanced rectal cancer: experience from a tertiary cancer centre from Southern India

et al. 2017

View full text Add to dashboard Cite

Background: Neoadjuvant concurrent chemoradiation (CTRT) is the recommended treatment for locally advanced rectal cancer. 5 Fluorouracil (5-FU) has been the standard chemotherapy drug, but recent studies have proved Capecitabine (CA) is as effective as 5-FU in terms of local response, distant recurrences and overall survival except toxicities. We conducted this study to evaluate acute toxicities and local response rates between 5-FU and CA as neoadjuvant treatment modality combined with radiation.Methods: All patients with newly biopsy proven adenocarcinoma of rectum of TNM stage T3N0/ any T with N1,N2 and in whom curative treatment was planned with concurrent chemoradiation dose of 5040cGy in 28 fractions were included in the study. From January 2013 to June 2014, a total of thirty patients were enrolled in this study, fifteen patients received 5-FU (arm A) and fifteen patients received CA (arm B) during concurrent chemoradiation. All patients were evaluated for acute toxicities during treatment using RTOG criteria. Local response was assessed radiographically after four weeks of completion of CTRT utilising RECIST (Response Evaluation Criteria in Solid Tumors) criteria and also assessed for surgery simultaneously. Postoperatively adjuvant chemotherapy was considered in all patients.Results: Grade III toxicities were more in 5-FU arm compared to CA arm. The local response rates were almost same in both the arms, partial response in 5-FU and CA arm were 53.3% and 60% respectively.Conclusions: This is the first Indian study comparing Capecitabine and continuous Infusional 5FU in neoadjuvant CTRT of standard advanced rectal cancer patients. Oral Capecitabine had same efficacy when compared to 5-FU in terms of local response rates as neoadjuvant treatment modality in locally advanced rectal cancer, but CA was better tolerated with better patient compliance and was less toxic.

show abstract

“…Patients often fail to follow up this therapy [9]. Xeloda is an oral fluoropyrimidine drug and has no cytotoxicity; while with TP, Xeloda turns into 5-Fu [10] in the tumor, which can cut into the tumor DNA strand and disturb its replication and repair and provide highly targeted tumor treatment.…”

Section: Discussionmentioning

confidence: 99%

Clinical analysis of concurrent 3DCRT and XELOX treatment for postoperative local recurrence of rectal carcinoma in elderly patients

Zhuang¹,

Xu²,

Xu³

et al. 2013

View full text Add to dashboard Cite

Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5‐fluorouracil and oral capecitabine

Abstract: Preoperative chemoradiotherapy with capecitabine for rectal cancer is efficacious and comparable to 5-FU (IV). It is more convenient, is well tolerated and avoids the need for inpatient admission.

Cited by 16 publications

References 63 publications

Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis

Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis

Comparison of continuous infusional 5-fluorouracil and capecitabine in preoperative chemo radiotherapy for locally advanced rectal cancer: experience from a tertiary cancer centre from Southern India

Clinical analysis of concurrent 3DCRT and XELOX treatment for postoperative local recurrence of rectal carcinoma in elderly patients

Contact Info

Product

Resources

About